Mirae Asset Global Investments’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$78.5K Sell
5,180
-755
-13% -$11.4K ﹤0.01% 1291
2026
Q1
$64.7K Buy
5,935
+493
+9% +$6.16K ﹤0.01% 1248
2025
Q4
$70.4K Buy
5,442
+1,120
+26% +$14.4K ﹤0.01% 1331
2025
Q3
$55.8K Buy
4,322
+15
+0.3% +$200 ﹤0.01% 1325
2025
Q2
$76.7K Buy
4,307
+629
+17% +$11K ﹤0.01% 1182
2025
Q1
$69.4K Buy
3,678
+72
+2% +$1.64K ﹤0.01% 1182
2024
Q4
$111K Sell
3,606
-308
-8% -$6.52K ﹤0.01% 1131
2024
Q3
$61.1K Buy
3,914
+701
+22% +$12.7K ﹤0.01% 1267
2024
Q2
$56.6K Buy
+3,213
New +$56.5K ﹤0.01% 1221
2021
Q4
Sell
-3,576
Closed -$415K 1700
2021
Q3
$415K Sell
3,576
-116
-3% -$17.5K ﹤0.01% 1531
2021
Q2
$819K Buy
3,692
+492
+15% +$95.7K ﹤0.01% 1326
2021
Q1
$423K Sell
3,200
-672
-17% -$106K ﹤0.01% 1339
2020
Q4
$670K Sell
3,872
-1,272
-25% -$174K ﹤0.01% 1240
2020
Q3
$573K Buy
+5,144
New +$411K ﹤0.01% 1159
2020
Q1
Sell
-2,750
Closed -$232K 1465
2019
Q4
$232K Buy
+2,750
New +$222K ﹤0.01% 1402

Other funds holding NVCR

Mirae Asset Global Investments's NVCR Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its NovoCure (NVCR) stake by 13% in Q2 2026, selling an estimated $11.4K and leaving 5,180 shares worth $78.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Mirae Asset Global Investments first reported a position in NVCR in Q4 2019 and has held it in 15 quarters since. The position peaked at $819K in Q2 2021. 76 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Mirae Asset Global Investments held 5,180 shares of NovoCure worth $78.5K as of Q2 2026.
  • Mirae Asset Global Investments sold 755 NovoCure shares in Q2 2026, an estimated $11.4K.
  • NovoCure made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1291 holding.
  • Mirae Asset Global Investments first reported a position in NovoCure in Q4 2019 and has held it in 15 quarters since.
  • Mirae Asset Global Investments's NovoCure position peaked at $819K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.